Bio-link Australia Pty. Ltd.

Bio-Link News

Please find below a list of recent news and press releases from Bio-Link.

17th July 2017 – Bio-Link’s Dr Lieven Huang Attending ‘Business of Regenerative Medicine’ in Toronto This Week

After winning a CCRM Australia grant, Bio-Link’s Dr Lieven Huang is attending the 2017 edition of ‘Business of Regenerative Medicine’ in Toronto, which is focused on the latest in commercialising regenerative medicine and stem cell therapies. The event is co-hosted by the Centre for Commercialization of Regenerative Medicine (CCRM) and the Rotman School of Management. More information about the event here.

 

8th May 2017 – Bio-Link Survey: Antibody(-like) Therapeutics in Australia

BIOLINK_logov2



Bio-Link is engaged by a client to scout for Australian therapeutics programs with antibodies and antibody-like drugs. All stages of development are considered, both within academia (e.g. Garvan Institute’s Centre for Targeted Therapies) and industry (e.g. CSL). The scouting results are likely to be shared with the global pharma industry, which might boost commercial R&D activities in Australia. Names of research groups or companies can be submitted below.
Thanks for your input!

Organisation Details

Name of Research Groups and/or Companies:
Technology/Program Specifics:




Bio-Link Australia Pty Ltd , www.bio-link.com
Suite 6/98 Glebe Point Road, Glebe, New South Wales, 2037
Level 2, Birdwood Offices, 19 Prospect Street, Box Hill, Victoria, 3128

BIOLINK_logov2

23rd May 2017 – Bio-Link Engaged by Kunovus Technologies

Bio-Link has been engaged by Kunovus Technologies to facilitate partnering of KT009, a preclinical, intra-intervertebral disk-administered regenerative biological therapy for the treatment of degenerative disk disease and chronic back pain. Kunovus Technologies has compelling preclinical data supporting KT009-mediated disk regeneration and subsequent reduction in pain. KT009 is poised to enter GMP manufacturing and formal preclinical assessment prior to clinical evaluation.

To learn more about this partnering opportunity, please click here.

Kunovus Technologies

16th May 2017 – Bio-Link Engaged by Actinogen Medical

Bio-Link has been engaged by Actinogen Medical to facilitate partnering of Xanamem™,a phase II, first-in-class, orally active, brain penetrant, potent and selective 11β-HSD1 inhibitor; designed to reduce regeneration of cortisol within the brain. Today, Actinogen Medical has announced treatment of the first patient in a global phase II clinical study investigating Xanamem™ for the treatment of Alzheimer’s disease.

To learn more about this partnering opportunity, please click here.

Actinogen

2nd May 2017 – Bio-Link Engaged by GenoFAB

Bio-Link has been engaged by GenoFAB to assist with the commercialisation of iVectors™, a new generation of intelligently designed, high-performance, custom protein expression vectors that have been optimized for upstream and downstream processing to rescue difficult-to-manufacture proteins.

To learn more about this partnering opportunity, please click here.

31st January 2017 – Bio-Link Engaged by Neural Diagnostics

Bio-Link has been engaged by Neural Diagnostics for the development of ElectroVestibuloGraphy (EVestG™), a novel medical device for the classification of neurological diseases. Bio-Link is seeking commercial partner(s) for licensing and commercial development of EVestG™ in the fields of clinical diagnostics, medical devices and drug development.

To learn more about this partnering opportunity, please click here.

Neural Diagnostics

29th August 2016 – Bio-Link Engaged by ShenQi Pharmaceutical

Bio-Link has been engaged by ShenQi Pharmaceutical (ShenQi), a subsidiary of ShenQi Group (GuiZhou, China), to scout for a strategic partner able to contribute advanced assisted reproductive technologies to a new business opportunity in the Chinese market.

To learn more about this partnering opportunity, please click here.

shenzen

28th July 2016 – “Realising Value from Biotechnology” – Bio-Link Published in Australasian Biotechnology

Bio-Link Executive Directors Christopher Boyer and Dr Christian Toouli have written an article for the recently published July addition of “Australasian Biotechnology” (volume 26, number 2). The article focuses on the need for biotechnology innovators to prioritise commercialisation, and in particular partnering, to realise maximum value from their assets. Please click here to read the article.

Older News